Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Feasibility of Lenalidomide in Combination With HLA-mismatched Stem-cell Microtransplantation as Post-remission Therapy in Patients With Acute Myeloid Leukemia (AML)

NCT02255162 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT02255162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02255162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Feasibility of Lenalidomide in Combination With HLA-mismatched Stem-cell Microtransplantation as Post-remission Therapy in Patients With Acute Myeloid Leukemia (AML)
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2015
Completion date
December 31, 2016
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute granulocytic leukemia, acute myelocytic leukemia, acute myelogenous leukemia, acute myeloid leukemia (aml), acute non-lymphocytic leukemia